Jin Tong

 

Jin Tong (Tom) Li has completed a term of suspension which ended on April 13, 2018, and his registration as a pharmacist has been reinstated. The registrant is limited from being a manager, director, or owner of a pharmacy, hold shares in any corporation that owns a pharmacy, and/or be a preceptor for a period of five years commencing April 14, 2018.


October 20, 2016
(April 13, 2018 – Registration reinstated)

Pursuant to s. 36(1) of the Health Professions Act, the Inquiry Committee has reached an agreement with Jin Tong (Tom) Li (the “Registrant”) to suspend his registration as a pharmacist for 540 consecutive days, from October 20, 2016 to April 13, 2018.

The Registrant acknowledged that between January 1, 2014 and December 22, 2014, he submitted fraudulent claims to PharmaCare over the PharmaNet system on over 2400 occasions. On all occasions, the Registrant had billed a high dollar value medication on PharmaNet, then reversed the medication to manipulate PharmaCare deductibles and to effectively allow patients to receive financial benefits from PharmaCare to which they were not entitled.

The Registrant also acknowledged that between January 1, 2013 and December 31, 2014, he had been the dispensing pharmacist and/or pharmacy manager responsible for multiple practice deficiencies including dispensing quantities in large excess of what had been authorized, dispensing from invalid prescriptions, dispensing from incomplete prescriptions, dispensing prescriptions under the incorrect prescriber’s name, dispensing incorrect medications, processing blood glucose test strips on PharmaNet in large excess of what could be accounted for by wholesaler invoices, and not keeping complete patient records and prescription documentation.

Prior to reinstatement of his registration following the suspension period, the Registrant will be required to:

  • thoroughly review relevant legislative requirements and to sign a Declaration acknowledging his understanding of and compliance with the legislative requirements;
  • to meet with the Inquiry Committee to discuss his reflections on his conduct and what he has learned; and
  • to complete an ethics course at his own expense.

The Registrant will also be limited from being a manager, director, or owner of a pharmacy, hold shares in any corporation that owns a pharmacy, and/or be a preceptor for a period of five years from the date that his suspension ends (commencing April 14, 2018).

The Inquiry Committee considers this agreement necessary to protect the public, as well as send a clear message to the profession that the College does not tolerate this type of conduct. 

Last Name: 
Li
Date of Dispositions: 
Friday, April 13, 2018